Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Tufts Study Shows Rise in Innovative Drug Partnerships | Contract Pharma

What are you searching for?

Sign in
Breaking News

Tufts Study Shows Rise in Innovative Drug Partnerships

Leading to more drugs in Phase I trials and shorter study times

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

A panel of research-based drug industry leaders recently convened by the Tufts Center for the Study of Drug Development (CSDD) reported that drug companies are engaging in innovative partnerships that are leading to more molecular entities entering Phase I trials and shorter study times.

“Drug developers have gotten the message that they need to innovate ‘better, faster, and cheaper’ — without sacrificing patient safety — and partnering is proving to be an effective strategy,” said Tufts CSDD Director Kenneth I Kaitin. “By aligning with others, drug developers are hoping to accelerate the translation of scientific findings into new medicines.”

According to Mr. Kaitin, one large pharmaceutical company, teaming with external partners, reported increasing the number of NMEs entering Phase I from an average of five a year to 16. The company also reported that it raised Phase II success rates from 14% to 41% during a recent five-year period.

The industry executives from the Tufts CSDD Executive Forum Roundtable also reported that: a new entity, known as a technology scout organization, is helping large pharma companies identify technologies and platforms that currently are not being commercialized; “umbrella agreements” with large universities enable developers to broaden relationships with individual researchers to identify marketable products; and trial sharing, where two companies share the same Phase I trial, has enabled developers to quickly learn whether joint administration of their compounds can enhance therapeutic outcomes.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics